- EQS-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: MorphoSys AG Reports First Quarter 2024 Financial Results
- EQS-News: MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
- EQS-News: MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
- EQS-NVR: MorphoSys AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
More ▼
Key statistics
On Friday, MorphoSys AG (MOR2:FRA) closed at 17.30, -0.57% below its 52-week high of 17.40, set on Feb 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.30 |
---|---|
High | 17.30 |
Low | 17.30 |
Bid | 17.30 |
Offer | 17.60 |
Previous close | 17.00 |
Average volume | 35.20 |
---|---|
Shares outstanding | 150.87m |
Free float | 126.33m |
P/E (TTM) | -- |
Market cap | 2.84bn USD |
EPS (TTM) | -3.41 USD |
Data delayed at least 15 minutes, as of May 17 2024 07:13 BST.
More ▼